These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 28949940)

  • 1. Optimal use of radium-223 in patients with metastatic castration-resistant prostate cancer.
    George DJ
    Clin Adv Hematol Oncol; 2017 Sep; 15(9):690-694. PubMed ID: 28949940
    [No Abstract]   [Full Text] [Related]  

  • 2. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.
    Li J; Armstrong AJ
    Clin Adv Hematol Oncol; 2015 May; 13(5):293-8. PubMed ID: 26352773
    [No Abstract]   [Full Text] [Related]  

  • 3. Radium-223 (Ra-223) Re-Treatment (Re-tx): First Experience From an International, Multicenter, Prospective Study in Patients (Pts) With Castration-Resistant Prostate Cancer and Bone Metastases (mCRPC).
    Clin Adv Hematol Oncol; 2016 Apr; 14(4 Suppl 5):10-1. PubMed ID: 27167843
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase II Clinical Study of Radium-223 Chloride (BAY 88-8223) in Japanese Patients With Symptomatic Castration-Resistant Prostate Cancer (CRPC) With Bone Metastases.
    Clin Adv Hematol Oncol; 2016 Apr; 14(4 Suppl 5):15-6. PubMed ID: 27167846
    [No Abstract]   [Full Text] [Related]  

  • 5. When to initiate treatment with radium-223 in patients with metastatic castration-resistant prostate cancer.
    Shore ND
    Clin Adv Hematol Oncol; 2016 Jan; 14(1):26-9. PubMed ID: 27057663
    [No Abstract]   [Full Text] [Related]  

  • 6. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Docetaxel still the optimal first choice for symptomatic metastatic castration-resistant prostate cancer.
    Dreicer R
    Clin Adv Hematol Oncol; 2015 May; 13(5):293-5. PubMed ID: 26352772
    [No Abstract]   [Full Text] [Related]  

  • 7. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
    Saad F; Carles J; Gillessen S; Heidenreich A; Heinrich D; Gratt J; Lévy J; Miller K; Nilsson S; Petrenciuc O; Tucci M; Wirth M; Federhofer J; O'Sullivan JM;
    Lancet Oncol; 2016 Sep; 17(9):1306-16. PubMed ID: 27473888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interim Results From ERADICATE: An Open-Label Phase 2 Study of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Castration-Resistant Prostate Cancer Subjects With Symptomatic Bone Metastases.
    Clin Adv Hematol Oncol; 2016 Apr; 14(4 Suppl 5):3-7. PubMed ID: 27167841
    [No Abstract]   [Full Text] [Related]  

  • 9. NICE guidance on radium-223 dichloride for hormone-relapsed prostate cancer with bone metastases.
    Umeweni N; Knight H; McVeigh G
    Lancet Oncol; 2016 Mar; 17(3):275-6. PubMed ID: 26827242
    [No Abstract]   [Full Text] [Related]  

  • 10. Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patients.
    Caffo O; Frantellizzi V; Monari F; Sbrana A; Costa RP; Pinto C; Tucci M; Baldari S; Facchini G; Bortolus R; Alongi F; Alongi P; Palermo A; Fanti S; Biasco E; Murabito A; Filice A; Zichi C; Pignata S; Borsatti E; Salgarello M; Spada M; Cortesi E; Vincentis G
    Future Oncol; 2021 Mar; 17(7):807-815. PubMed ID: 33508980
    [No Abstract]   [Full Text] [Related]  

  • 11. Review of Radium-223 and Metastatic Castration-Sensitive Prostate Cancer.
    Dandapani SV; Wong J; Twardowski P
    Cancer Biother Radiopharm; 2020 Sep; 35(7):490-496. PubMed ID: 32762539
    [No Abstract]   [Full Text] [Related]  

  • 12. Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated?
    Serretta V; Valerio MR; Costa R; Tripoli V; Murabito A; Princiotta A; Scalici Gesolfo C; Borsellino N; Verderame F; Gebbia V; Licari M; Sanfilippo C;
    Urol Oncol; 2019 Dec; 37(12):964-969. PubMed ID: 31601517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.
    Matsubara N; Nagamori S; Wakumoto Y; Uemura H; Kimura G; Yokomizo A; Kikukawa H; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Tsutsui H; Uemura H
    Int J Clin Oncol; 2018 Feb; 23(1):173-180. PubMed ID: 28770408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radium-223 in Metastatic Castration-Resistant Prostate Cancer: Clinical Development and Use in Contemporary Practice.
    Morgan SC
    J Med Imaging Radiat Sci; 2019 Dec; 50(4S1):S26-S30. PubMed ID: 31231006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist's perspective.
    Shore ND
    Urology; 2015 Apr; 85(4):717-24. PubMed ID: 25681834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radium-223 outcomes after multiple lines of metastatic castration-resistant prostate cancer therapy in clinical practice: implication of pre-treatment spinal epidural disease.
    Spratt DE; Osborne JR; Zumsteg ZS; Rebeiz K; Leeman J; Rivera A; Morris MJ; Zelefsky MJ
    Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):271-6. PubMed ID: 27112529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating Changes in Immune Function and Bone Microenvironment During Radium-223 Treatment of Patients with Castration-Resistant Prostate Cancer.
    Dorff TB; Stein C; Kortylewski M; Posadas E; Synold T; Quinn D
    Cancer Biother Radiopharm; 2020 Sep; 35(7):485-489. PubMed ID: 32366119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of metastatic castration-resistant prostate cancer: A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel.
    Baldari S; Boni G; Bortolus R; Caffo O; Conti G; De Vincentis G; Monari F; Procopio G; Santini D; Seregni E; Valdagni R
    Crit Rev Oncol Hematol; 2017 May; 113():43-51. PubMed ID: 28427521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer - Therapy with radium-223.
    Brito AE; Amorim BJ; Martello M; Bernardo WM; Etchebehere E;
    Rev Assoc Med Bras (1992); 2017 Dec; 63(12):1019-1023. PubMed ID: 29489974
    [No Abstract]   [Full Text] [Related]  

  • 20. Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety.
    Nilsson S
    Expert Opin Drug Saf; 2015 Jul; 14(7):1127-36. PubMed ID: 26022669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.